For research use only
| Cat No. | ABC-RC029Y |
| Product Type | Reporter Stable Cell Lines |
| Cell Type | B Lymphocyte |
| Species | Human |
| Host Cell | RPMI-8226 |
| Source Organ | Peripheral Blood |
| Disease | Myeloma |
| Storage | Liquid Nitrogen |
RPMI-8226/Luciferase Stable Cell Line by AcceGen for sensitive bioluminescent tracking of multiple myeloma progression and drug response in vivo.
RPMI-8226/Luciferase Stable Cell Line is a genetically engineered human multiple myeloma model developed through stable integration of luciferase into RPMI-8226 cells. This engineered cell line maintains characteristic plasma cell morphology and retains native multiple myeloma markers (CD38, CD138) while enabling sensitive, quantitative tracking of tumor progression. The constitutive luciferase expression permits real-time monitoring of tumor growth kinetics, metastatic spread, and treatment response through non-invasive bioluminescence imaging. Particularly valuable for preclinical drug development and metastasis studies, this cell line provides high sensitivity for detecting minimal residual disease in animal models. Cryopreserved at low passage (<P20) to ensure stable reporter expression and genetic integrity. The cells are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast and Bacteria.
| Species | Human |
| Cat.No | ABC-RC029Y |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | B Lymphocyte |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Myeloma |
| Biosafety Level | 2 |
| Storage | Liquid Nitrogen |
| Product Type | Reporter Stable Cell Lines |
| Host Cell | RPMI-8226 |
| Gene Info | Luciferase |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The RPMI-8226/Luciferase Stable Cell Line is an engineered variant of the human multiple myeloma cell line RPMI-8226 with stable luciferase (Luc) expression. This bioluminescent reporter enables sensitive, quantitative tracking of tumor growth and metastasis in both in vitro assays and in vivo xenograft models using D-luciferin substrate. Particularly valuable for high-throughput drug screening and longitudinal therapy monitoring, this cell line provides non-invasive measurement of tumor burden via bioluminescence imaging (BLI). Maintain in standard RPMI-1640 medium with appropriate antibiotic selection.